Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Novartis
Novartis
Lyell Immunopharma, Inc.
University of Texas Southwestern Medical Center
AVM Biotechnology Inc
New York Medical College
BeOne Medicines
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Hackensack Meridian Health
Genmab
Genmab
AvenCell Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Dizal Pharmaceuticals
Vironexis Biotherapeutics Inc.
Pfizer
Galapagos NV
TICAROS Co., Ltd.
University of Chicago
Jonsson Comprehensive Cancer Center
Monte Rosa Therapeutics, Inc
Bristol-Myers Squibb
Medical College of Wisconsin
BeOne Medicines
Ohio State University Comprehensive Cancer Center
Tanabe Pharma Corporation
Sun Yat-sen University
SymBio Pharmaceuticals
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
University of Michigan Rogel Cancer Center
Incyte Corporation
Masonic Cancer Center, University of Minnesota
Fred Hutchinson Cancer Center
Dana-Farber Cancer Institute
Fred Hutchinson Cancer Center
Genmab
Incyte Corporation
University of Washington
Bambino Gesù Hospital and Research Institute
Ipsen
Incyte Corporation
Immunitas Therapeutics
University of Washington
Karyopharm Therapeutics Inc
Ohio State University Comprehensive Cancer Center
Barbara Ann Karmanos Cancer Institute
Sichuan Baili Pharmaceutical Co., Ltd.
Institut Curie
BeiGene